Based on these findings, a recombinant human RNase1 fused with the IgG1 Fc portion (RNase-Fc) that degrades RNA in ICs was expected to be effective in the treatment of SS patients possessing anti-Ro/SSA antibodies. This evidence concerns the gene RNASE1 and synovial sarcoma.